Payment overview · 2025
General Payments
$83.58
5 reported records · 5 companies
Healthcare provider profile · identity verified
R Keith Davis, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SMACKOVER, AR · NPI 1104826320
Verified facts
What the public records show
CMS Open Payments records show R Keith Davis, M.D. received $83.58 in general payments during 2025 across 5 reported records.
HARMONY BIOSCIENCES LLC accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $20.21 | 24.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.81 | 21.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.61 | 19.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.25 | 18.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.70 | 16.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.58 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 455 | 53 |
| Alprazolam | Alprazolam | 234 | 24 |
| Omeprazole | Omeprazole | 197 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 36 |
| Potassium Chloride | Potassium Chloride | 181 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 176 | 38 |
| Tramadol Hcl | Tramadol Hcl | 172 | 32 |
| Gabapentin | Gabapentin | 171 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 30 |
| Metformin Hcl Er | Metformin Hcl | 152 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 145 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 137 | 27 |
| Furosemide | Furosemide | 137 | 27 |
| Losartan Potassium | Losartan Potassium | 133 | 25 |
| Glimepiride | Glimepiride | 131 | 27 |
| Clonazepam | Clonazepam | 127 | 15 |
| Diazepam | Diazepam | 105 | 12 |
| Meloxicam | Meloxicam | 104 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 17 |
| Cefdinir | Cefdinir | 90 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 11 |
| Ozempic | Semaglutide | 87 | 13 |
| Allopurinol | Allopurinol | 86 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 30 |
| Lisinopril | Lisinopril | 85 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 12 |
| Azithromycin | Azithromycin | 79 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 20 |
| Ezetimibe | Ezetimibe | 75 | 12 |
| Methylprednisolone | Methylprednisolone | 72 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 11 |
| Jardiance | Empagliflozin | 64 | 11 |
| Valsartan | Valsartan | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 58 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Prednisone | Prednisone | 52 | 13 |
| Trazodone Hcl | Trazodone Hcl | 51 | suppressed |
| Simvastatin | Simvastatin | 50 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Eliquis | Apixaban | 49 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 12 |
| Famotidine | Famotidine | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 46 | 15 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Dexamethasone | Dexamethasone | 45 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Metformin Hcl | Metformin Hcl | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 35 |
| Baclofen | Baclofen | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 19 |
| Fluconazole | Fluconazole | 31 | 17 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Acarbose | Acarbose | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 19 |
| Mupirocin | Mupirocin | 26 | 18 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.58 · 5 records | HARMONY BIOSCIENCES LLC | BREZTRI, Ozempic, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, WAKIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error